United Statessanodynetherapeutics.com
Sanodyne Therapeutics, Inc. is a biopharmaceutical company focused on the research and development of novel therapeutics for neurology and pain-related conditions. The company advances drug candidates through preclinical and early clinical stages with the aim of addressing unmet medical needs in nerve-related disorders.
Sanodyne’s activities include translational research, clinical development, and collaboration with external partners through licensing and development agreements. Its work centers on building a pipeline of innovative therapies with the potential to improve outcomes for patients with neuropathic and other pain syndromes.
None yet. When a new project in the record names Sanodyne Therapeutics, Inc. as owner, partner or investor, it shows here.
Sanodyne gains rights to develop TRK-750 for neuropathy. SNT-001 shows promise in trials, with Phase II planned. Collaboration aims to advance treatment options.
